Extended Data Fig. 6. Deletion of NR4A1 in CD8⁺ T cells enhances immunity against tumours.

a–c, CD45.1⁺CD45.2⁺ (B6SJL × C57BL6) recipient mice were injected subcutaneously with E.G7 tumour cells (5 × 10⁵ cells per mouse) in one flank. Six days later, the mice were adoptively transferred with PBS, wild-type or Nr4a1^{− /−} OT-I cells (3 × 10⁶ cells per mouse) intravenously. Mice were euthanized 6 days after T cell transfer. Donor-derived T cells were collected from tumour, draining lymph nodes and spleens, and subjected to flow cytometry analysis. a, b, Flow cytometry analysis and quantification of IFNγ expression (a ) and TNF expression (b ) in donor-derived T cells from tumours. c, Flow cytometry analysis and quantification of the T cell exhaustion surface markers PD-1 and TIM-3 in tumour-infiltrating donor T cells. d, Experimental strategy for assay of adoptively transferred T cells in tumour-bearing mice. e, Sizes of E.G7 tumour. f, Flow cytometry analysis of PD-1 and TIM-3 expression in tumour-infiltrating donor cells, and quantification of total cellularity of tumour infiltrating donor cells. g, Histogram showing PD-1, TIM-3 and BCL-2 expression in tumour-infiltrating donor T cells. h, Flow cytometry analysis and quantification of IFNγ and TNF expression in tumour-infiltrating donor cells after OT-I peptide restimulation. i, Flow cytometry analysis and quantification of CD107A expression in tumour-infiltrating donor cells. n = 5 mice (8 weeks old) per group. P values were calculated using a two-sided unpaired Student’s t-test. Data are representative of three individual experiments and graphs show mean ± s.d.